Repurposed drugs for the treatment of schizophrenia and bipolar disorders

Current Topics in Medicinal Chemistry

Volumn 13, Issue 18, 2013, Pages 2364-2385

  Bumb, J M ^a   Enning, F ^a   Leweke, F M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adherence; Antipsychotics; Medical need; Omega 3 fatty acids; Oxytocin; Treatment resistance

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CARBAMAZEPINE; CELECOXIB; ERYTHROPOIETIN; ESTRADIOL; FOLIC ACID; HALOPERIDOL; HOMOCYSTEINE; LAMOTRIGINE; MINOCYCLINE; MIRTAZAPINE; MODAFINIL; OMEGA 3 FATTY ACID; OXCARBAZEPINE; OXYTOCIN; PLACEBO; PRAMIPEXOLE; PRASTERONE; PREGNENOLONE; RALOXIFENE; VALPROIC ACID;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ARTICLE; BIPOLAR DISORDER; DRUG EFFICACY; DRUG MEGADOSE; DRUG REPOSITIONING; HUMAN; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; BIPOLAR DISORDER; DRUG REPOSITIONING; HUMANS; SCHIZOPHRENIA;

EID: 84887872780     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113136660165     Document Type: Article

References (195)

1. Ban, T. A. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat, 2007, 3 (4), 495-500.
2. Collins, P. Y.; Patel, V.; Joestl, S. S.; March, D.; Insel, T. R.; Daar, A. S.; Anderson, W.; Dhansay, M. A.; Phillips, A.; Shurin, S.; Walport, M.; Ewart, W.; Savill, S. J.; Bordin, I. A.; Costello, E. J.; Durkin, M.; Fairburn, C.; Glass, R. I.; Hall, W.; Huang, Y.; Hyman, S. E.; Jamison, K.; Kaaya, S.; Kapur, S.; Kleinman, A.; Ogunniyi, A.; Otero-Ojeda, A.; Poo, M. M.; Ravindranath, V.; Sahakian, B. J.; Saxena, S.; Singer, P. A.; Stein, D. J. Grand challenges in global mental health. Nature, 2011, 475 (7354), 27-30.
3. Robinson, D. G.; Woerner, M. G.; McMeniman, M.; Mendelowitz, A.; Bilder, R. M. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry, 2004, 161 (3), 473-9.
4. Harrison, G.; Hopper, K.; Craig, T.; Laska, E.; Siegel, C.; Wanderling, J.; Dube, K. C.; Ganev, K.; Giel, R.; an der Heiden, W.; Holmberg, S. K.; Janca, A.; Lee, P. W.; Leon, C. A.; Malhotra, S.; Marsella, A. J.; Nakane, Y.; Sartorius, N.; Shen, Y.; Skoda, C.; Thara, R.; Tsirkin, S. J.; Varma, V. K.; Walsh, D.; Wiersma, D. Recovery from psychotic illness: a 15-and 25-year international follow-up study. Br J Psychiatry, 2001, 178, 506-17.
5. Saha, S.; Chant, D.; McGrath, J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry, 2007, 64 (10), 1123-31.
6. Lieberman, J. A.; Stroup, T. S.; McEvoy, J. P.; Swartz, M. S.; Rosenheck, R. A.; Perkins, D. O.; Keefe, R. S.; Davis, S. M.; Davis, C. E.; Lebowitz, B. D.; Severe, J.; Hsiao, J. K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 2005, 353 (12), 1209-23.
7. Jones, P. B.; Barnes, T. R.; Davies, L.; Dunn, G.; Lloyd, H.; Hayhurst, K. P.; Murray, R. M.; Markwick, A.; Lewis, S. W. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry, 2006, 63 (10), 1079-87.
8. Kahn, R. S.; Fleischhacker, W. W.; Boter, H.; Davidson, M.; Vergouwe, Y.; Keet, I. P.; Gheorghe, M. D.; Rybakowski, J. K.; Galderisi, S.; Libiger, J.; Hummer, M.; Dollfus, S.; Lopez-Ibor, J. J.; Hranov, L. G.; Gaebel, W.; Peuskens, J.; Lindefors, N.; Riecher-Rossler, A.; Grobbee, D. E.; group, E. s. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet, 2008, 371 (9618), 1085-97.
9. Lacro, J. P.; Dunn, L. B.; Dolder, C. R.; Leckband, S. G.; Jeste, D. V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry, 2002, 63 (10), 892-909.
10. Fenton, W. S.; Blyler, C. R.; Heinssen, R. K. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull, 1997, 23 (4), 637-51.
11. Torrey, E. F.; Davis, J. M. Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. Clin Schizophr Relat Psychoses, 2012, 5 (4), 208-216.
12. Cipriani, A.; Barbui, C.; Salanti, G.; Rendell, J.; Brown, R.; Stockton, S.; Purgato, M.; Spineli, L. M.; Goodwin, G. M.; Geddes, J. R. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet, 2011, 378 (9799), 1306-15.
13. Ascher-Svanum, H.; Zhu, B.; Faries, D. E.; Lacro, J. P.; Dolder, C. R.; Peng, X. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence, 2008, 2, 67-77.
14. Vane, J. R.; Botting, R. M. The mechanism of action of aspirin. Thromb Res, 2003, 110 (5-6), 255-8.
15. Yasuda, O.; Takemura, Y.; Kawamoto, H.; Rakugi, H. Aspirin: recent developments. Cell Mol Life Sci, 2008, 65 (3), 354-8.
16. Dickerson, F.; Stallings, C.; Origoni, A.; Boronow, J.; Yolken, R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res, 2007, 93 (1-3), 261-5.
17. Dickerson, F.; Stallings, C.; Origoni, A.; Vaughan, C.; Khushalani, S.; Yolken, R. Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr Res, 2012, 134 (1), 83-8.
18. Fan, X.; Pristach, C.; Liu, E. Y.; Freudenreich, O.; Henderson, D. C.; Goff, D. C. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res, 2007, 149 (1-3), 267-71.
19. Suvisaari, J.; Loo, B. M.; Saarni, S. E.; Haukka, J.; Perala, J.; Saarni, S. I.; Viertio, S.; Partti, K.; Lonnqvist, J.; Jula, A. Inflammation in psychotic disorders: a population-based study. Psychiatry Res, 2011, 189 (2), 305-11.
20. Dickerson, F.; Stallings, C.; Origoni, A.; Boronow, J.; Yolken, R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31 (4), 952-5.
21. Goldstein, B. I.; Kemp, D. E.; Soczynska, J. K.; McIntyre, R. S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry, 2009, 70 (8), 1078-90.
22. Ramadan, E.; Basselin, M.; Chang, L.; Chen, M.; Ma, K.; Rapoport, S. I. Chronic lithium feeding reduces upregulated brain arachidonic acid metabolism in HIV-1 transgenic rat. J Neuroimmune Pharmacol, 2012, 7 (3), 701-13.
23. Saetre, P.; Emilsson, L.; Axelsson, E.; Kreuger, J.; Lindholm, E.; Jazin, E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry, 2007, 7, 46.
24. Diaz, F. J.; Perez-Iglesias, R.; Mata, I.; Martinez-Garcia, O.; Vazquez-Barquero, J. L.; de Leon, J.; Crespo-Facorro, B. Possible effects of some antipsychotic drugs on C-reactive protein in a drugnaive psychotic sample. Schizophr Res, 2010, 121 (1-3), 207-12.
25. Laan, W.; Grobbee, D. E.; Selten, J. P.; Heijnen, C. J.; Kahn, R. S.; Burger, H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry, 2010, 71 (5), 520-7.
26. McCormack, P. L. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs, 2011, 71 (18), 2457-89.
27. Muller, N.; Riedel, M.; Scheppach, C.; Brandstatter, B.; Sokullu, S.; Krampe, K.; Ulmschneider, M.; Engel, R. R.; Moller, H. J.; Schwarz, M. J. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry, 2002, 159 (6), 1029-34.
28. Rapaport, M. H.; Delrahim, K. K.; Bresee, C. J.; Maddux, R. E.; Ahmadpour, O.; Dolnak, D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry, 2005, 57 (12), 1594-6.
29. Akhondzadeh, S.; Tabatabaee, M.; Amini, H.; Ahmadi Abhari, S. A.; Abbasi, S. H.; Behnam, B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res, 2007, 90 (1-3), 179-85.
30. Muller, N.; Krause, D.; Dehning, S.; Musil, R.; Schennach-Wolff, R.; Obermeier, M.; Moller, H. J.; Klauss, V.; Schwarz, M. J.; Riedel, M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res, 2010, 121 (1-3), 118-24.
31. Nery, F. G.; Monkul, E. S.; Hatch, J. P.; Fonseca, M.; Zunta-Soares, G. B.; Frey, B. N.; Bowden, C. L.; Soares, J. C. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol, 2008, 23 (2), 87-94.
32. Dean, O. M.; Data-Franco, J.; Giorlando, F.; Berk, M. Minocycline: therapeutic potential in psychiatry. CNS Drugs, 2012, 26 (5), 391-401.
33. Chaves, C.; Marque, C. R.; Trzesniak, C.; Machado de Sousa, J. P.; Zuardi, A. W.; Crippa, J. A.; Dursun, S. M.; Hallak, J. E. Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update. Braz J Med Biol Res, 2009, 42 (11), 1002-14.
34. Miyaoka, T.; Yasukawa, R.; Yasuda, H.; Hayashida, M.; Inagaki, T.; Horiguchi, J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31 (1), 304-7.
35. Miyaoka, T.; Yasukawa, R.; Yasuda, H.; Hayashida, M.; Inagaki, T.; Horiguchi, J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol, 2008, 31 (5), 287-92.
36. Chaudhry, I. B.; Hallak, J.; Husain, N.; Minhas, F.; Stirling, J.; Richardson, P.; Dursun, S.; Dunn, G.; Deakin, B. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol, 2012, 26 (9), 1185-93.
37. Levkovitz, Y.; Mendlovich, S.; Riwkes, S.; Braw, Y.; Levkovitch-Verbin, H.; Gal, G.; Fennig, S.; Treves, I.; Kron, S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry, 2010, 71 (2), 138-49.
38. Savitz, J.; Preskorn, S.; Teague, T. K.; Drevets, D.; Yates, W.; Drevets, W. Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, doubleblind, placebo-controlled, 2x2 clinical trial. BMJ Open, 2012, 2 (1), e000643.
39. Levine, J.; Cholestoy, A.; Zimmerman, J. Possible antidepressant effect of minocycline. Am J Psychiatry, 1996, 153 (4), 582.
40. Anttila, S. A.; Leinonen, E. V. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev, 2001, 7 (3), 249-64.
41. Berk, M.; Gama, C. S.; Sundram, S.; Hustig, H.; Koopowitz, L.; D'Souza, R.; Malloy, H.; Rowland, C.; Monkhouse, A.; Monkhouse, A.; Bole, F.; Sathiyamoorthy, S.; Piskulic, D.; Dodd, S. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebocontrolled clinical trial. Hum Psychopharmacol, 2009, 24 (3), 233-8.
42. Berk, M.; Ichim, C.; Brook, S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol, 2001, 16 (2), 87-92.
43. Zoccali, R.; Muscatello, M. R.; Cedro, C.; Neri, P.; La Torre, D.; Spina, E.; Di Rosa, A. E.; Meduri, M. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol, 2004, 19 (2), 71-6.
44. Joffe, G.; Terevnikov, V.; Joffe, M.; Stenberg, J. H.; Burkin, M.; Tiihonen, J. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr Res, 2009, 108 (1-3), 245-51.
45. Abbasi, S. H.; Behpournia, H.; Ghoreshi, A.; Salehi, B.; Raznahan, M.; Rezazadeh, S. A.; Rezaei, F.; Akhondzadeh, S. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res, 2010, 116 (2-3), 101-6.
46. Poyurovsky, M.; Epshtein, S.; Fuchs, C.; Schneidman, M.; Weizman, R.; Weizman, A. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebocontrolled pilot study. J Clin Psychopharmacol, 2003, 23 (3), 305-8.
47. Poyurovsky, M.; Pashinian, A.; Weizman, R.; Fuchs, C.; Weizman, A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo-and propranolol-controlled trial. Biol Psychiatry, 2006, 59 (11), 1071-7.
48. Terevnikov, V.; Stenberg, J. H.; Tiihonen, J.; Chukhin, E.; Joffe, M.; Burkin, M.; Joffe, G. Relationships between pharmacotherapyinduced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial. Int J Neuropsychopharmacol, 2012, 1-6, epub ahead.
49. Stenberg, J. H.; Terevnikov, V.; Joffe, M.; Tiihonen, J.; Chukhin, E.; Burkin, M.; Joffe, G. Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia--a path model investigation. Neuropharmacology, 2013, 64, 248-53.
50. Habermeyer, B.; Bayer, U.; Muller-Spahn, F. Mania associated with mirtazepine treatment and mixed depression. Pharmacopsychiatry, 2010, 43 (1), 37-8.
51. Basavraj, V.; Nanjundappa, G. B.; Chandra, P. S. Mirtazapine induced mania in a woman with major depression in the absence of features of bipolarity. Aust N Z J Psychiatry, 2011, 45 (10), 901.
52. Kumar, R. Approved and investigational uses of modafinil: an evidence-based review. Drugs, 2008, 68 (13), 1803-39.
53. Scoriels, L.; Jones, P. B.; Sahakian, B. J. Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology, 2013, 64, 168-84.
54. Rosenthal, M. H.; Bryant, S. L. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin Neuropharmacol, 2004, 27 (1), 38-43.
55. Turner, D. C.; Clark, L.; Pomarol-Clotet, E.; McKenna, P.; Robbins, T. W.; Sahakian, B. J. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology, 2004, 29 (7), 1363-73.
56. Pierre, J. M.; Peloian, J. H.; Wirshing, D. A.; Wirshing, W. C.; Marder, S. R. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J Clin Psychiatry, 2007, 68 (5), 705-10.
57. Freudenreich, O.; Henderson, D. C.; Macklin, E. A.; Evins, A. E.; Fan, X.; Cather, C.; Walsh, J. P.; Goff, D. C. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebocontrolled pilot trial. J Clin Psychiatry, 2009, 70 (12), 1674-80.
58. Henderson, D. C.; Freudenreich, O.; Borba, C. P.; Wang, X.; Copeland, P. M.; Macklin, E.; Fan, X.; Cather, C.; Goff, D. C. Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophr Res, 2011, 130 (1-3), 53-6.
59. Scoriels, L.; Barnett, J. H.; Murray, G. K.; Cherukuru, S.; Fielding, M.; Cheng, F.; Lennox, B. R.; Sahakian, B. J.; Jones, P. B. Effects of modafinil on emotional processing in first episode psychosis. Biol Psychiatry, 2011, 69 (5), 457-64.
60. Arbabi, M.; Bagheri, M.; Rezaei, F.; Ahmadi-Abhari, S. A.; Tabrizi, M.; Khalighi-Sigaroudi, F.; Akhondzadeh, S. A placebocontrolled study of the modafinil added to risperidone in chronic schizophrenia. Psychopharmacology (Berl), 2012, 220 (3), 591-8.
61. Frye, M. A.; Grunze, H.; Suppes, T.; McElroy, S. L.; Keck, P. E., Jr.; Walden, J.; Leverich, G. S.; Altshuler, L. L.; Nakelsky, S.; Hwang, S.; Mintz, J.; Post, R. M. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry, 2007, 164 (8), 1242-9.
62. Dell'osso, B.; Timtim, S.; Hooshmand, F.; Miller, S.; Wang, P. W.; Hill, S. J.; Portillo, N.; Ketter, T. A. Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatmentresistant bipolar disorder. J Affect Disord, 2012.
63. Camacho, A.; Ng, B.; Frye, M. A. Modafinil for bipolar depression with comorbid methamphetamine abuse. Am J Addict, 2010, 19 (2), 190-1.
64. Anderson, A. L.; Li, S. H.; Biswas, K.; McSherry, F.; Holmes, T.; Iturriaga, E.; Kahn, R.; Chiang, N.; Beresford, T.; Campbell, J.; Haning, W.; Mawhinney, J.; McCann, M.; Rawson, R.; Stock, C.; Weis, D.; Yu, E.; Elkashef, A. M. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend, 2012, 120 (1-3), 135-41.
65. Bond, D. J.; Hadjipavlou, G.; Lam, R. W.; McIntyre, R. S.; Beaulieu, S.; Schaffer, A.; Weiss, M.; Canadian Network for, M.; Anxiety Treatments Task, F. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry, 2012, 24 (1), 23-37.
66. Kaufman, K. R. Antiepileptic drugs in the treatment of psychiatric disorders. Epilepsy Behav, 2011, 21 (1), 1-11.
67. Turner, W. J. The usefulness of diphenylhydantoin in treatment of non-epileptic emotional disorders. Int J Neuropsychiatry, 1967, 3, Suppl 2: 8-20.
68. Okuma, T.; Kishimoto, A.; Inoue, K.; Matsumoto, H.; Ogura, A. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report. Folia Psychiatr Neurol Jpn, 1973, 27 (4), 283-97.
69. Lambert, P. A.; Venaud, G. [Use of valpromide in psychiatric therapeutics]. Encephale, 1987, 13 (6), 367-73.
70. Emrich, H. M.; Dose, M.; von Zerssen, D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord, 1985, 8 (3), 243-50.
71. Emrich, H. M.; von Zerssen, D.; Kissling, W.; Moller, H. J. Therapeutic effect of valproate in mania. Am J Psychiatry, 1981, 138 (2), 256.
72. Emrich, H. M.; von Zerssen, D.; Kissling, W.; Moller, H. J.; Windorfer, A. Effect of sodium valproate on mania. The GABAhypothesis of affective disorders. Arch Psychiatr Nervenkr, 1980, 229 (1), 1-16.
73. Emrich, H. M.; Wolf, R. Valproate treatment of mania. Prog Neuropsychopharmacol Biol Psychiatry, 1992, 16 (5), 691-701.
74. Hayes, J.; Prah, P.; Nazareth, I.; King, M.; Walters, K.; Petersen, I.; Osborn, D. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database, 1995-2009. PLoS One, 2011, 6 (12), e28725.
75. Rogawski, M. A.; Loscher, W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med, 2004, 10 (7), 685-92.
76. Johannessen Landmark, C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs, 2008, 22 (1), 27-47.
77. Grunze, H. C. The effectiveness of anticonvulsants in psychiatric disorders. Dialogues Clin Neurosci, 2008, 10 (1), 77-89.
78. Cunningham, M. O.; Jones, R. S. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology, 2000, 39 (11), 2139-46.
79. Waldmeier, P. C.; Baumann, P. A.; Wicki, P.; Feldtrauer, J. J.; Stierlin, C.; Schmutz, M. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology, 1995, 45 (10), 1907-13.
80. Klein, E.; Bental, E.; Lerer, B.; Belmaker, R. H. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry, 1984, 41 (2), 165-70.
81. Dose, M.; Apelt, S.; Emrich, H. M. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res, 1987, 22 (4), 303-10.
82. Carpenter, W. T., Jr.; Kurz, R.; Kirkpatrick, B.; Hanlon, T. E.; Summerfelt, A. T.; Buchanan, R. W.; Waltrip, R. W.; Breier, A. Carbamazepine maintenance treatment in outpatient schizophrenics. Arch Gen Psychiatry, 1991, 48 (1), 69-72.
83. Nachshoni, T.; Levin, Y.; Levy, A.; Kritz, A.; Neumann, M. A double-blind trial of carbamazepine in negative symptom schizophrenia. Biol Psychiatry, 1994, 35 (1), 22-6.
84. Leucht, S.; Kissling, W.; McGrath, J.; White, P. Carbamazepine for schizophrenia. Cochrane Database Syst Rev, 2007, (3), CD001258.
85. Arif, H.; Buchsbaum, R.; Weintraub, D.; Pierro, J.; Resor, S. R., Jr.; Hirsch, L. J. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav, 2009, 14 (1), 202-9.
86. Hellewell, J. S. Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J Affect Disord, 2002, 72 Suppl 1, S23-34.
87. Reinares, M.; Rosa, A. R.; Franco, C.; Goikolea, J. M.; Fountoulakis, K.; Siamouli, M.; Gonda, X.; Frangou, S.; Vieta, E. A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. Int J Neuropsychopharmacol, 2013, 16 (2), 485-96.
88. Leweke, F. M.; Gerth, C. W.; Koethe, D.; Faulhaber, J.; Klosterkotter, J. Oxcarbazepine as an adjunct for schizophrenia. Am J Psychiatry, 2004, 161 (6), 1130-1.
89. Calabrese, J. R.; Huffman, R. F.; White, R. L.; Edwards, S.; Thompson, T. R.; Ascher, J. A.; Monaghan, E. T.; Leadbetter, R. A. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord, 2008, 10 (2), 323-33.
90. Geddes, J. R.; Calabrese, J. R.; Goodwin, G. M. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry, 2009, 194 (1), 4-9.
91. Tiihonen, J.; Wahlbeck, K.; Kiviniemi, V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res, 2009, 109 (1-3), 10-4.
92. Goff, D. C.; Keefe, R.; Citrome, L.; Davy, K.; Krystal, J. H.; Large, C.; Thompson, T. R.; Volavka, J.; Webster, E. L. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol, 2007, 27 (6), 582-9.
93. Dose, M.; Hellweg, R.; Yassouridis, A.; Theison, M.; Emrich, H. M. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry, 1998, 31 (4), 122-5.
94. Casey, D. E.; Daniel, D. G.; Tamminga, C.; Kane, J. M.; Tran-Johnson, T.; Wozniak, P.; Abi-Saab, W.; Baker, J.; Redden, L.; Greco, N.; Saltarelli, M. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology, 2009, 34 (5), 1330-8.
95. Schwarz, C.; Volz, A.; Li, C.; Leucht, S. Valproate for schizophrenia. Cochrane Database Syst Rev, 2008, (3), CD004028.
96. Basan, A.; Kissling, W.; Leucht, S. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophr Res, 2004, 70 (1), 33-7.
97. Suzuki, T.; Uchida, H.; Takeuchi, H.; Nakajima, S.; Nomura, K.; Tanabe, A.; Yagi, G.; Watanabe, K.; Kashima, H. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum Psychopharmacol, 2009, 24 (8), 628-38.
98. Dean, O.; Giorlando, F.; Berk, M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci, 2011, 36 (2), 78-86.
99. Berk, M.; Copolov, D.; Dean, O.; Lu, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Judd, F.; Katz, F.; Katz, P.; Ording-Jespersen, S.; Little, J.; Conus, P.; Cuenod, M.; Do, K. Q.; Bush, A. I. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry, 2008, 64 (5), 361-8.
100. Lavoie, S.; Murray, M. M.; Deppen, P.; Knyazeva, M. G.; Berk, M.; Boulat, O.; Bovet, P.; Bush, A. I.; Conus, P.; Copolov, D.; Fornari, E.; Meuli, R.; Solida, A.; Vianin, P.; Cuenod, M.; Buclin, T.; Do, K. Q. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology, 2008, 33 (9), 2187-99.
101. Bulut, M.; Savas, H. A.; Altindag, A.; Virit, O.; Dalkilic, A. Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. World J Biol Psychiatry, 2009, 10 (4 Pt 2), 626-8.
102. Asevedo, E.; Cunha, G. R.; Zugman, A.; Mansur, R. B.; Brietzke, E. N-acetylcysteine as a potentially useful medication to prevent conversion to schizophrenia in at-risk individuals. Rev Neurosci, 2012, 23 (4), 353-62.
103. Magalhaes, P. V.; Dean, O. M.; Bush, A. I.; Copolov, D. L.; Malhi, G. S.; Kohlmann, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Berk, M. N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J Affect Disord, 2011, 129 (1-3), 317-20.
104. Berk, M.; Copolov, D. L.; Dean, O.; Lu, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Bush, A. I. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry, 2008, 64 (6), 468-75.
105. Magalhaes, P. V.; Dean, O. M.; Bush, A. I.; Copolov, D. L.; Malhi, G. S.; Kohlmann, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Berk, M. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr, 2011, 33 (4), 374-8.
106. Berk, M.; Dean, O.; Cotton, S. M.; Gama, C. S.; Kapczinski, F.; Fernandes, B. S.; Kohlmann, K.; Jeavons, S.; Hewitt, K.; Allwang, C.; Cobb, H.; Bush, A. I.; Schapkaitz, I.; Dodd, S.; Malhi, G. S. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord, 2011, 135 (1-3), 389-94.
107. Antonini, A.; Barone, P.; Ceravolo, R.; Fabbrini, G.; Tinazzi, M.; Abbruzzese, G. Role of pramipexole in the management of Parkinson's disease. CNS Drugs, 2010, 24 (10), 829-41.
108. Antonini, A.; Calandrella, D. Pharmacokinetic evaluation of pramipexole. Expert Opin Drug Metab Toxicol, 2011, 7 (10), 1307-14.
109. Tokunaga, N.; Choudhury, M. E.; Nishikawa, N.; Nagai, M.; Tujii, T.; Iwaki, H.; Kaneta, M.; Nomoto, M. Pramipexole upregulates dopamine receptor D(2) and D(3) expression in rat striatum. J Pharmacol Sci, 2012, 120 (2), 133-7.
110. Kissling, W.; Mackert, A.; Bfiuml, J.; Lauter, H., Erste klinische Erfahrungen mit dem neuen Dopamin-Autorezeptoragonisten. In Biologische Psychiatrie, Gaebel, W.; Laux, G., Eds. Springer: Berlin, 1991; pp 249-256.
111. Magyar, I.; Martényi, F.; J., H.; Fekete, S.; Ozsváth, K.; Janka, Z.; Szilárd, J.; Beck, J.; Schaefer, E., Pramipexole-a new partial dopamine agonist in the treatment of negative symptoms of chronic schizophrenic patients. In ECNP Congress, Budapest, 1993.
112. Kasper, S.; Barnas, C.; Heiden, A.; Volz, H. P.; Laakmann, G.; Zeit, H.; Pfolz, H. Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. Eur Neuropsychopharmacol, 1997, 7 (1), 65-70.
113. Kelleher, J. P.; Centorrino, F.; Huxley, N. A.; Bates, J. A.; Drake, J. K.; Egli, S.; Baldessarini, R. J. Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment. Eur Neuropsychopharmacol, 2012, 22 (6), 415-8.
114. Burdick, K. E.; Braga, R. J.; Nnadi, C. U.; Shaya, Y.; Stearns, W. H.; Malhotra, A. K. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry, 2012, 73 (1), 103-12.
115. Goldberg, J. F.; Burdick, K. E.; Endick, C. J. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry, 2004, 161 (3), 564-6.
116. Zarate, C. A., Jr.; Payne, J. L.; Singh, J.; Quiroz, J. A.; Luckenbaugh, D. A.; Denicoff, K. D.; Charney, D. S.; Manji, H. K. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry, 2004, 56 (1), 54-60.
117. Lattanzi, L.; Dell'Osso, L.; Cassano, P.; Pini, S.; Rucci, P.; Houck, P. R.; Gemignani, A.; Battistini, G.; Bassi, A.; Abelli, M.; Cassano, G. B. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord, 2002, 4 (5), 307-14.
118. Perugi, G.; Toni, C.; Ruffolo, G.; Frare, F.; Akiskal, H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry, 2001, 34 (4), 137-41.
119. Sporn, J.; Ghaemi, S. N.; Sambur, M. R.; Rankin, M. A.; Recht, J.; Sachs, G. S.; Rosenbaum, J. F.; Fava, M. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry, 2000, 12 (3), 137-40.
120. Arcasoy, M. O. The non-haematopoietic biological effects of erythropoietin. Br J Haematol, 2008, 141 (1), 14-31.
121. Brines, M.; Cerami, A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci, 2005, 6 (6), 484-94.
122. Donati, A. WORLD TRAFFIC IN DOPING SUBSTANCES; WADA-World Anti-Doping Agency:, 2007.
123. Ehrenreich, H.; Hinze-Selch, D.; Stawicki, S.; Aust, C.; Knolle-Veentjer, S.; Wilms, S.; Heinz, G.; Erdag, S.; Jahn, H.; Degner, D.; Ritzen, M.; Mohr, A.; Wagner, M.; Schneider, U.; Bohn, M.; Huber, M.; Czernik, A.; Pollmacher, T.; Maier, W.; Siren, A. L.; Klosterkotter, J.; Falkai, P.; Ruther, E.; Aldenhoff, J. B.; Krampe, H. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry, 2007, 12 (2), 206-20.
124. Wustenberg, T.; Begemann, M.; Bartels, C.; Gefeller, O.; Stawicki, S.; Hinze-Selch, D.; Mohr, A.; Falkai, P.; Aldenhoff, J. B.; Knauth, M.; Nave, K. A.; Ehrenreich, H. Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia. Mol Psychiatry, 2011, 16 (1), 26-36, 1.
125. Miyamoto, S.; Jarskog, L. F.; Fleischhacker, W. W. Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials. Curr Opin Psychiatry, 2013.
126. Miskowiak, K. W.; Vinberg, M.; Harmer, C. J.; Ehrenreich, H.; Knudsen, G. M.; Macoveanu, J.; Hansen, A. R.; Paulson, O. B.; Siebner, H. R.; Kessing, L. V. Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials, 2010, 11, 97.
127. Miyamoto, S.; Miyake, N.; Jarskog, L. F.; Fleischhacker, W. W.; Lieberman, J. A. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry, 2012, 17 (12), 1206-27.
128. Clemett, D.; Spencer, C. M. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs, 2000, 60 (2), 379-411.
129. Naessen, S.; Carlstrom, K.; Bystrom, B.; Pierre, Y.; Hirschberg, A. L. Effects of an antiandrogenic oral contraceptive on appetite and eating behavior in bulimic women. Psychoneuroendocrinology, 2007, 32 (5), 548-54.
130. Bergemann, N.; Abu-Tair, F.; Strowitzki, T. Estrogen in the treatment of late-onset schizophrenia. J Clin Psychopharmacol, 2007, 27 (6), 718-20.
131. Kulkarni, J.; de Castella, A.; Smith, D.; Taffe, J.; Keks, N.; Copolov, D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res, 1996, 20 (3), 247-52.
132. Kulkarni, J.; Riedel, A.; de Castella, A. R.; Fitzgerald, P. B.; Rolfe, T. J.; Taffe, J.; Burger, H. Estrogen-a potential treatment for schizophrenia. Schizophr Res, 2001, 48 (1), 137-44.
133. Akhondzadeh, S.; Nejatisafa, A. A.; Amini, H.; Mohammadi, M. R.; Larijani, B.; Kashani, L.; Raisi, F.; Kamalipour, A. Adjunctive estrogen treatment in women with chronic schizophrenia: a doubleblind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry, 2003, 27 (6), 1007-12.
134. Behdani F; Hebrani P; Mohamad Nejad M Adjunctive estrogen treatment in women with chronic schizophrenia admitted in Hejazi and Ibn-e-Sina (abstract). Eur Neuropsychopharmacol, 2008, (18(Suppl), 390.
135. Bergemann, N.; Mundt, C.; Parzer, P.; Pakrasi, M.; Eckstein-Mannsperger, U.; Haisch, S.; Salbach, B.; Klinga, K.; Runnebaum, B.; Resch, F. Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. Schizophr Res, 2005, 74 (2-3), 125-34.
136. Lindamer, L. A.; Lohr, J. B.; Harris, M. J.; Jeste, D. V. Gender, estrogen, and schizophrenia. Psychopharmacol Bull, 1997, 33 (2), 221-8.
137. Louza, M. R.; Marques, A. P.; Elkis, H.; Bassitt, D.; Diegoli, M.; Gattaz, W. F. Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophr Res, 2004, 66 (2-3), 97-100.
138. Kulkarni, J.; Gurvich, C.; Lee, S. J.; Gilbert, H.; Gavrilidis, E.; de Castella, A.; Berk, M.; Dodd, S.; Fitzgerald, P. B.; Davis, S. R. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology, 2010, 35 (8), 1142-7.
139. Ghafari, E.; Fararouie, M.; Shirazi, H. G.; Farhangfar, A.; Ghaderi, F.; Mohammadi, A. Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia. Clin Schizophr Relat Psychoses, 2013, 6 (4), 172-6.
140. Chouinard, G.; Steinberg, S.; Steiner, W. Estrogen-progesterone combination: another mood stabilizer? Am J Psychiatry, 1987, 144 (6), 826.
141. Usall, J.; Huerta-Ramos, E.; Iniesta, R.; Cobo, J.; Araya, S.; Roca, M.; Serrano-Blanco, A.; Teba, F.; Ochoa, S. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry, 2011, 72 (11), 1552-7.
142. Viero, C.; Shibuya, I.; Kitamura, N.; Verkhratsky, A.; Fujihara, H.; Katoh, A.; Ueta, Y.; Zingg, H. H.; Chvatal, A.; Sykova, E.; Dayanithi, G. REVIEW: Oxytocin: Crossing the bridge between basic science and pharmacotherapy. CNS Neurosci Ther, 2010, 16 (5), e138-56.
143. Caldwell, H. K.; Stephens, S. L.; Young, W. S., 3rd Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol Psychiatry, 2009, 14 (2), 190-6.
144. Rubin, L. H.; Carter, C. S.; Drogos, L.; Pournajafi-Nazarloo, H.; Sweeney, J. A.; Maki, P. M. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res, 2010, 124 (1-3), 13-21.
145. Feifel, D.; Macdonald, K.; Nguyen, A.; Cobb, P.; Warlan, H.; Galangue, B.; Minassian, A.; Becker, O.; Cooper, J.; Perry, W.; Lefebvre, M.; Gonzales, J.; Hadley, A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry, 2010, 68 (7), 678-80.
146. Pedersen, C. A.; Gibson, C. M.; Rau, S. W.; Salimi, K.; Smedley, K. L.; Casey, R. L.; Leserman, J.; Jarskog, L. F.; Penn, D. L. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res, 2011, 132 (1), 50-3.
147. Averbeck, B. B.; Bobin, T.; Evans, S.; Shergill, S. S. Emotion recognition and oxytocin in patients with schizophrenia. Psychol Med, 2011, 1-8.
148. Feifel, D.; Macdonald, K.; Cobb, P.; Minassian, A. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. Schizophr Res, 2012, 139 (1-3), 207-10.
149. Modabbernia, A.; Rezaei, F.; Salehi, B.; Jafarinia, M.; Ashrafi, M.; Tabrizi, M.; Hosseini, S. M.; Tajdini, M.; Ghaleiha, A.; Akhondzadeh, S. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs, 2013, 27 (1), 57-65.
150. Baulieu, E. E. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology, 1998, 23 (8), 963-87.
151. Ritsner, M. S. Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials. CNS Neurosci Ther, 2010, 16 (1), 32-44.
152. Ritsner, M. S. The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia. Neuroscience, 2011, 191, 91-100.
153. Marx, C. E.; Bradford, D. W.; Hamer, R. M.; Naylor, J. C.; Allen, T. B.; Lieberman, J. A.; Strauss, J. L.; Kilts, J. D. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience, 2011, 191, 78-90.
154. Marx, C. E.; Stevens, R. D.; Shampine, L. J.; Uzunova, V.; Trost, W. T.; Butterfield, M. I.; Massing, M. W.; Hamer, R. M.; Morrow, A. L.; Lieberman, J. A. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology, 2006, 31 (6), 1249-63.
155. Gallagher, P.; Watson, S.; Smith, M. S.; Young, A. H.; Ferrier, I. N. Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophr Res, 2007, 90 (1-3), 258-65.
156. Marx, C. E.; Keefe, R. S.; Buchanan, R. W.; Hamer, R. M.; Kilts, J. D.; Bradford, D. W.; Strauss, J. L.; Naylor, J. C.; Payne, V. M.; Lieberman, J. A.; Savitz, A. J.; Leimone, L. A.; Dunn, L.; Porcu, P.; Morrow, A. L.; Shampine, L. J. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology, 2009, 34 (8), 1885-903.
157. Ritsner, M. S.; Gibel, A.; Shleifer, T.; Boguslavsky, I.; Zayed, A.; Maayan, R.; Weizman, A.; Lerner, V. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, doubleblind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry, 2010, 71 (10), 1351-62.
158. Osuji, I. J.; Vera-Bolanos, E.; Carmody, T. J.; Brown, E. S. Pregnenolone for cognition and mood in dual diagnosis patients. Psychiatry Res, 2010, 178 (2), 309-12.
159. Strous, R. D.; Maayan, R.; Lapidus, R.; Stryjer, R.; Lustig, M.; Kotler, M.; Weizman, A. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry, 2003, 60 (2), 133-41.
160. Nachshoni, T.; Ebert, T.; Abramovitch, Y.; Assael-Amir, M.; Kotler, M.; Maayan, R.; Weizman, A.; Strous, R. D. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophr Res, 2005, 79 (2-3), 251-6.
161. Strous, R. D.; Stryjer, R.; Maayan, R.; Gal, G.; Viglin, D.; Katz, E.; Eisner, D.; Weizman, A. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, doubleblind placebo controlled trial. Psychoneuroendocrinology, 2007, 32 (2), 96-105.
162. Markowitz, J. S.; Carson, W. H.; Jackson, C. W. Possible dihydroepiandrosterone-induced mania. Biol Psychiatry, 1999, 45 (2), 241-2.
163. Kline, M. D.; Jaggers, E. D. Mania onset while using dehydroepiandrosterone. Am J Psychiatry, 1999, 156 (6), 971.
164. Kalra, E. K. Nutraceutical--definition and introduction. AAPS PharmSci, 2003, 5 (3), E25.
165. Hill, M.; Shannahan, K.; Jasinski, S.; Macklin, E. A.; Raeke, L.; Roffman, J. L.; Goff, D. C. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res, 2011, 127 (1-3), 41-5.
166. Sylvia, L. G.; Peters, A. T.; Deckersbach, T.; Nierenberg, A. A. Nutrient-based therapies for bipolar disorder: a systematic review. Psychother Psychosom, 2013, 82 (1), 10-9.
167. Godfrey, P. S.; Toone, B. K.; Carney, M. W.; Flynn, T. G.; Bottiglieri, T.; Laundy, M.; Chanarin, I.; Reynolds, E. H. Enhancement of recovery from psychiatric illness by methylfolate. Lancet, 1990, 336 (8712), 392-5.
168. Goff, D. C.; Bottiglieri, T.; Arning, E.; Shih, V.; Freudenreich, O.; Evins, A. E.; Henderson, D. C.; Baer, L.; Coyle, J. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry, 2004, 161 (9), 1705-8.
169. Levine, J.; Stahl, Z.; Sela, B. A.; Ruderman, V.; Shumaico, O.; Babushkin, I.; Osher, Y.; Bersudsky, Y.; Belmaker, R. H. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry, 2006, 60 (3), 265-9.
170. Burghardt, K. J.; Ellingrod, V. L. Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy: is there a role for folate? Mol Diagn Ther, 2013, 17 (1), 21-30.
171. Coppen, A.; Chaudhry, S.; Swade, C. Folic acid enhances lithium prophylaxis. J Affect Disord, 1986, 10 (1), 9-13.
172. Dittmann, S.; Seemuller, F.; Grunze, H. C.; Schwarz, M. J.; Zach, J.; Fast, K.; Born, C.; Dargel, S.; Engel, R. R.; Bernhard, B.; Moller, H. J.; Riedel, M.; Severus, W. E. The impact of homocysteine levels on cognition in euthymic bipolar patients: a cross-sectional study. J Clin Psychiatry, 2008, 69 (6), 899-906.
173. Dittmann, S.; Seemuller, F.; Schwarz, M. J.; Kleindienst, N.; Stampfer, R.; Zach, J.; Born, C.; Bernhard, B.; Fast, K.; Grunze, H.; Engel, R. R.; Severus, E. Association of cognitive deficits with elevated homocysteine levels in euthymic bipolar patients and its impact on psychosocial functioning: preliminary results. Bipolar Disord, 2007, 9 (1-2), 63-70.
174. Behzadi, A. H.; Omrani, Z.; Chalian, M.; Asadi, S.; Ghadiri, M. Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial. Acta Psychiatr Scand, 2009, 120 (6), 441-5.
175. Horrobin, D. F.; Bennett, C. N., Phospholipid Spectrum Disorders in Psychiatry and Neurology. 2nd ed.; Marius: Carnforth, Lanashire, 2003.
176. Emsley, R.; Oosthuizen, P.; van Rensburg, S. J. Clinical potential of omega-3 fatty acids in the treatment of schizophrenia. CNS Drugs, 2003, 17 (15), 1081-91.
177. Amminger, G. P.; McGorry, P. D. Update on omega-3 polyunsaturated fatty acids in early-stage psychotic disorders. Neuropsychopharmacology, 2012, 37 (1), 309-10.
178. Horrobin, D. F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res, 1998, 30 (3), 193-208.
179. Stafford, M. R.; Jackson, H.; Mayo-Wilson, E.; Morrison, A. P.; Kendall, T. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ, 2013, 346, f185.
180. Amminger, G. P.; Schafer, M. R.; Papageorgiou, K.; Klier, C. M.; Cotton, S. M.; Harrigan, S. M.; Mackinnon, A.; McGorry, P. D.; Berger, G. E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebocontrolled trial. Arch Gen Psychiatry, 2010, 67 (2), 146-54.
181. Emsley, R.; Myburgh, C.; Oosthuizen, P.; van Rensburg, S. J. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry, 2002, 159 (9), 1596-8.
182. Peet, M.; Horrobin, D. F.; Group, E. E. M. S. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res, 2002, 36 (1), 7-18.
183. Berger, G. E.; Proffitt, T. M.; McConchie, M.; Yuen, H.; Wood, S. J.; Amminger, G. P.; Brewer, W.; McGorry, P. D. Ethyleicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J Clin Psychiatry, 2007, 68 (12), 1867-75.
184. Fenton, W. S.; Dickerson, F.; Boronow, J.; Hibbeln, J. R.; Knable, M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry, 2001, 158 (12), 2071-4.
185. Peet, M.; Brind, J.; Ramchand, C. N.; Shah, S.; Vankar, G. K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res, 2001, 49 (3), 243-51.
186. Stoll, A. L.; Severus, W. E.; Freeman, M. P.; Rueter, S.; Zboyan, H. A.; Diamond, E.; Cress, K. K.; Marangell, L. B. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebocontrolled trial. Arch Gen Psychiatry, 1999, 56 (5), 407-12.
187. Frangou, S.; Lewis, M.; McCrone, P. Efficacy of ethyleicosapentaenoic acid in bipolar depression: randomised doubleblind placebo-controlled study. Br J Psychiatry, 2006, 188, 46-50.
188. Osher, Y.; Belmaker, R. H. Omega-3 fatty acids in depression: a review of three studies. CNS Neurosci Ther, 2009, 15 (2), 128-33.
189. Osher, Y.; Bersudsky, Y.; Belmaker, R. H. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small openlabel study. J Clin Psychiatry, 2005, 66 (6), 726-9.
190. Clayton, E. H.; Hanstock, T. L.; Hirneth, S. J.; Kable, C. J.; Garg, M. L.; Hazell, P. L. Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr, 2009, 63 (8), 1037-40.
191. Murphy, B. L.; Stoll, A. L.; Harris, P. Q.; Ravichandran, C.; Babb, S. M.; Carlezon, W. A., Jr.; Cohen, B. M. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial. J Clin Psychopharmacol, 2012, 32 (5), 699-703.
192. Keck, P. E., Jr.; Mintz, J.; McElroy, S. L.; Freeman, M. P.; Suppes, T.; Frye, M. A.; Altshuler, L. L.; Kupka, R.; Nolen, W. A.; Leverich, G. S.; Denicoff, K. D.; Grunze, H.; Duan, N.; Post, R. M. Double-blind, randomized, placebo-controlled trials of ethyleicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry, 2006, 60 (9), 1020-2.
193. Evans, S. J.; Kamali, M.; Prossin, A. R.; Harrington, G. J.; Ellingrod, V. L.; McInnis, M. G.; Burant, C. F. Association of plasma omega-3 and omega-6 lipids with burden of disease measures in bipolar subjects. J Psychiatr Res, 2012, 46 (11), 1435-41.
194. Hiemke, C.; Baumann, P.; Bergemann, N.; Conca, A.; Dietmaier, O.; Egberts, K.; Fric, M.; Gerlach, M.; Greiner, C.; Grunder, G.; Haen, E.; Havemann-Reinecke, U.; Jaquenoud Sirot, E.; Kirchherr, H.; Laux, G.; Lutz, U. C.; Messer, T.; Muller, M. J.; Pfuhlmann, B.; Rambeck, B.; Riederer, P.; Schoppek, B.; Stingl, J.; Uhr, M.; Ulrich, S.; Waschgler, R.; Zernig, G. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update, 2011. Pharmacopsychiatry, 2011, 44 (6), 195-235.
195. Ruhrmann, S.; Klosterkotter, J.; Bodatsch, M.; Bechdolf, A.; Schimmelmann, B. G.; Nikolaides, A.; Hilboll, D.; Schultze-Lutter, F. Pharmacological prevention and treatment in clinical at-risk states for psychosis. Curr Pharm Des, 2012, 18 (4), 550-7.